- Home
- HTH vs PTGX Comparison
HTH vs PTGX Comparison
Compare HTH & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HTH | PTGX |
|---|---|---|
| Founded | 1998 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 5.2B |
| IPO Year | 2003 | 2016 |
Fundamental Metrics
Financial Performance| Metric | HTH | PTGX |
|---|---|---|
| Price | $35.78 | $103.02 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 12 |
| Target Price | $37.50 | ★ $106.67 |
| AVG Volume (30 Days) | 311.2K | ★ 807.6K |
| Earning Date | 04-23-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.23% | N/A |
| EPS Growth | ★ 51.72 | N/A |
| EPS | ★ 2.64 | N/A |
| Revenue | ★ $152,188,000.00 | N/A |
| Revenue This Year | N/A | $867.86 |
| Revenue Next Year | $3.22 | N/A |
| P/E Ratio | $13.60 | ★ N/A |
| Revenue Growth | ★ 15.52 | N/A |
| 52 Week Low | $27.35 | $39.60 |
| 52 Week High | $40.41 | $107.84 |
Technical Indicators
Market Signals| Indicator | HTH | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 49.27 | 62.28 |
| Support Level | $33.79 | $76.63 |
| Resistance Level | $37.30 | N/A |
| Average True Range (ATR) | 0.67 | 4.88 |
| MACD | 0.16 | 0.13 |
| Stochastic Oscillator | 84.00 | 76.48 |
Price Performance
Historical ComparisonAbout HTH Hilltop Holdings Inc.
Hilltop Holdings Inc is a Dallas-based financial holding company. The company has three segments: The banking segment includes the operations of the Bank; The broker-dealer segment includes the operations of Securities Holdings,; and the mortgage origination segment is composed of PrimeLending. Majority of revenue is from Broker-dealer Segment.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.